BAJAJ BROKING
Dr Reddy’s Laboratories Ltd has sold 14 ANDAs to Senores Pharmaceuticals for an undisclosed amount. The portfolio, valued between $421 million and $1.13 billion in the US market, includes FDA-approved controlled substances and general drugs. Dr Reddy share price remained flat at ₹11,120.15.
Dr Reddy’s Laboratories Ltd has finalised an agreement to sell a portfolio of 14 Abbreviated New Drug Applications (ANDAs) to Ahmedabad-based Senores Pharmaceuticals Ltd. The acquisition, funded by Senores’ recent IPO proceeds of ₹5.82 billion, will help the company expand its presence in the regulated US market. The financial terms of the deal have not been disclosed.
Also read: Welspun Specialty Wins ₹231.77 Crore BHEL Contract for Boiler Tubes
Number of ANDAs Sold: 14 (13 FDA-approved, 1 pending approval)
US Market Valuation: Estimated between $421 million and $1.13 billion
Acquirer: Senores Pharmaceuticals Ltd
Funding Source: ₹5.82 billion IPO proceeds from December
Product Categories: Controlled substances and general category drugs
Market Focus: US, with growth potential in other regulated and semi-regulated markets
Also read: Power Grid Wins Bids for 3 Interstate Transmission Projects Under BOOT Model
The 14 ANDAs acquired by Senores Pharma include controlled substances and general drugs that cater to various healthcare segments, including government procurement, retail chains, and specialty clinics. The total addressable market for these drugs in the US is projected to be between $421 million and $1.13 billion.
The acquisition is expected to strengthen Senores’ footprint in the US pharmaceutical market while complementing its expansion strategy in other regulated territories. The company plans to leverage its manufacturing and distribution network to maximise market penetration.
Transaction Details | Information |
Number of ANDAs | 14 (13 FDA-approved, 1 pending) |
Estimated US Market Value | $421 million - $1.13 billion |
Acquirer | Senores Pharmaceuticals Ltd |
Funding Source | ₹5.82 billion IPO proceeds |
Product Categories | Controlled substances, generics |
Target Markets | US, regulated, and semi-regulated markets |
Following the announcement, Dr Reddy share price remained nearly flat, closing at ₹11,120.15 on the National Stock Exchange (NSE). Meanwhile, Senores Pharmaceuticals’ stock surged 6.03% to ₹562.50, reflecting investor optimism about the company’s expansion in the US pharmaceutical market.
Dr Reddy’s Laboratories Ltd’s sale of its 14-drug portfolio to Senores Pharma highlights its strategic shift in portfolio management. The transaction allows Senores Pharma to expand in the US market while Dr Reddy share price remained steady. The completion of regulatory approvals will determine the impact of this deal on both companies in the coming months.
Also read: Apollo Hospitals Invests ₹250 Crore in India’s First Proteus One System
Do you have a trading account app or demat account app?
You can open an account with Bajaj Broking in minutes.
Download the Bajaj Broking app now from Play Store or App Store.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://www.bajajbroking.in/disclaimer
Share this article:
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading